Cancer-related investigator-initiated trials with an intervention involving a drug, device, or biologic are subject to review by the Data and Safety Monitoring Committee (DSMC).
DSMC reviews study information depending on type of trial (as outlined below) and may recommend continuation, suspension, or closure of a study.
A DSMC Annual Renewal Form is required for all studies undergoing review by the DSMC.
Study Information Reviewed by the DSMC
Stephen Smith, MD
Heather Cheng, MD, PhD
Samantha Culwell, PharmD
Chad He, PhD
Biostatistics, Public Health Sciences
Natasha Hunter, MD
Elizabeth Krakow, MD, CM, MS
Hematologic Malignancies, Immunotherapy
John Liao, MD, PhD
Gynecologic Oncology, Public Health Sciences
Christina Poh, MD
Rachael Safyan, MD
Katherine Tarlock, MD
Hematologic Malignancies, Pediatric Oncology
Diane Tseng, MD, PhD
Lung, Head and Neck Malignancies
Masumi Ueda, MD, MA
Hematologic Malignancies, Transplantation